Which statement best describes analogues of natural ligands in drug design?

Which statement best describes analogues of natural ligands in drug design?

• A. A target-centered approach using a validated biochemical target.
• B. A high-throughput method that screens thousands of compounds.
• C. A compound-centered approach that uses the natural ligand of a receptor as the starting point for drug development.
• D. A form of rational drug design based on the 3D structure of a target.

Answer: (C)

Ligand-based drug design uses knowledge of existing ligands to guide the creation of new compounds. When the starting point is a natural (endogenous) ligand, the approach focuses on modifying that ligand to preserve the essential interactions with the receptor while improving properties like potency, selectivity, and pharmacokinetics. This keeps the core binding features—the pharmacophore—intact, then tunes other parts of the molecule to enhance performance. This stands in contrast to target-centered methods, which start from the receptor or enzyme itself and try to fit a molecule to that site without necessarily relying on a known ligand. It also differs from high-throughput screening that shuffles through large libraries of compounds with little prior ligand knowledge, and from structure-based design that uses the target’s 3D structure to guide de novo molecule creation rather than starting from a known ligand.

Ligand-based drug design uses knowledge of existing ligands to guide the creation of new compounds. When the starting point is a natural (endogenous) ligand, the approach focuses on modifying that ligand to preserve the essential interactions with the receptor while improving properties like potency, selectivity, and pharmacokinetics. This keeps the core binding features—the pharmacophore—intact, then tunes other parts of the molecule to enhance performance.

This stands in contrast to target-centered methods, which start from the receptor or enzyme itself and try to fit a molecule to that site without necessarily relying on a known ligand. It also differs from high-throughput screening that shuffles through large libraries of compounds with little prior ligand knowledge, and from structure-based design that uses the target’s 3D structure to guide de novo molecule creation rather than starting from a known ligand.